title: Monitoring of tumor response to cisplatin with simultaneous fluorescence and positron emission tomography: a feasibility study.
abstract: Dual modality molecular imaging can capture concurrent molecular events and evaluate therapeutic efficacy from uniquely different perspectives based on different molecular targets. In this work, dual modality tomographic imaging, (18) F-fluorodeoxyglucose based positron emission tomography and subsurface fluorescence molecular tomography ([(18) F]FDG-PET/subsurface FMT), is proposed to monitor tumor response to cisplatin on a mouse xenograft model in vivo. One mouse was administered with cisplatin (1.0 mg/kg) by intraperitoneal injection once every day for 14 days, and another mouse was administered with saline to serve as the control. Dual modality [(18) F]FDG-PET/subsurface FMT imaging was conducted on days 0, 2, 5, 9, 15, and 22. In vivo imaging and quantitative analysis demonstrated the feasibility of [(18) F]FDG-PET/subsurface FMT imaging in tracking the changes of [(18) F]FDG tumor uptake and amount of red fluorescent protein (RFP) synthesized by tumor cells in the same mouse simultaneously. Dual modality [(18) F]FDG-PET/subsurface FMT imaging may thus provide a powerful tool for better understanding disease progress and treatment evaluation from different perspectives.
authors.affiliation: Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing 100084, China.
authors.forename: Fei
authors.initials: F
authors.lastname: Liu
authors.forename: Xu
authors.initials: X
authors.lastname: Cao
authors.forename: Shuangquan
authors.initials: S
authors.lastname: Liu
authors.forename: Bin
authors.initials: B
authors.lastname: Zhang
authors.forename: Wei
authors.initials: W
authors.lastname: He
authors.forename: Jinping
authors.initials: J
authors.lastname: Song
authors.forename: Zhongquan
authors.initials: Z
authors.lastname: Dai
authors.forename: Bin
authors.initials: B
authors.lastname: Zhang
authors.forename: Jianwen
authors.initials: J
authors.lastname: Luo
authors.forename: Yinghui
authors.initials: Y
authors.lastname: Li
authors.forename: Baoci
authors.initials: B
authors.lastname: Shan
authors.forename: Jing
authors.initials: J
authors.lastname: Bai
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000627:therapeutic use*; D018450:Disease Progression; D005240:Feasibility Studies; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000737:chemistry; D006801:Humans; D007274:Injections, Intraperitoneal; D008164:Luminescent Proteins / Q000737:chemistry; D051379:Mice; D008807:Mice, Inbred BALB C; D008856:Microscopy, Fluorescence / Q000379:methods*; D057054:Molecular Imaging; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D049268:Positron-Emission Tomography / Q000379:methods*; D000097573:Red Fluorescent Protein
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin; D019788:Fluorodeoxyglucose F18; D008164:Luminescent Proteins; D000097573:Red Fluorescent Protein
keywords: [18F]FDG-PET; dual modality; fluorescence; molecular imaging; tomography